The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC

被引：0
|
作者：
Sarina, Piha-Paul
Xu, Binghe
Fan, Ying
Yuan, Yuan
Lavasani, Sayeh
Mortimer, Joanne
Goel, Sanjay
Tsimberidou, Apostolia
Ibrahim, Nuhad
Abouharb, Sausan
Barcenas, Carlos
Lheme, Adaeze
Karp, Daniel
Ahnert, Jordi Rodon
Dumbrava, Ecaterina
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Hennessy, Katie
Fu, Ximei
Xu, Ruolan
Ni, Shumao
Wu, Frank
Meric-Bernstam, Funda
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-RF01-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RF01-07
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [22] RETROSPECTIVE OBSERVATIONAL STUDY OF REALWORLD TREATMENT PATTERNS AND FINANCIAL BURDEN IN PATIENTS WITH PREMENOPAUSAL METASTATIC HR+/HER2-BREAST CANCER
    Koh, H.
    Park, Y. H.
    Jung, J.
    VALUE IN HEALTH, 2023, 26 (12) : S514 - S514
  • [23] A phase 2 study of abemaciclib in patients with leptomeningeal metastases secondary to HR+, HER2-breast cancer
    Tolaney, S. M.
    Sahebjam, S.
    Le Rhun, E.
    Lin, Nu
    Bear, M. Markel
    Yang, Z.
    Chen, Y.
    Anders, C. K.
    CANCER RESEARCH, 2019, 79 (04)
  • [24] Metastatic HR+/HER2-Breast Cancer Real-World Data support the clinical Benefits of Palbociclib
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [25] Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer
    Wander, S. A.
    Spring, L. M.
    Stein, C. R.
    Yuen, M.
    Zangardi, M.
    O'Shaughnessy, J.
    Bardia, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [26] Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2-breast cancer (BC) cohorts of EV-202
    Giordano, Antonio
    Awan, Arif Ali Ali
    Bruce, Justine Yang
    Rugo, Hope S.
    Diamond, Jennifer Robinson
    Novik, Yelena
    Baranda, Joaquina Celebre
    Muro, Kei
    Ono, Makiko
    Nanda, Rita
    Kaplan, Jason
    Gorla, Seema Rao
    Liu, Shubin
    Wozniak, Michele
    Lee, Anthony
    Traina, Tiffany A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Real-world safety and effectiveness of ribociclib in Korean patients with HR+/HER2-locally advanced or metastatic breast cancer
    Kim, J. H.
    Chang, M-C.
    Kim, T-H.
    Seo, J. H.
    Kim, J-J.
    Won, H. S.
    Seong, M-K.
    Kang, Y.
    Lee, Y.
    Lee, K-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1419 - S1420
  • [28] COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY
    Altundag, K.
    Basaran, G.
    Oksuzoglu, B.
    Oven, B.
    Ozguroglu, M.
    Aydin, D.
    Hacibedel, B.
    Helvacioglu, K.
    Tuna, E.
    Tatar, M.
    VALUE IN HEALTH, 2016, 19 (03) : A146 - A146
  • [29] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024,
  • [30] RESOURCE UTILIZATION AND COST FOR WOMEN WITH ADVANCED HR+/HER2-BREAST CANCER IN COLOMBIAN HEALTH CARE SETTINGS
    Franco, S.
    Lobaton, J. F.
    Aruachan, S.
    Montoya, M. E.
    Rojas, G.
    Londono, P. A.
    Kurosky, S.
    Alarcon, B. A.
    Matiz, G. A.
    Reyes Sanchez, J. M.
    Castano Gamboa, N.
    VALUE IN HEALTH, 2019, 22 : S476 - S476
12345